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CancerCancer is the ﬁnal result of the accumulation of several genetic alterations occurring in a cell. Several
herpesviruses and especially gamma-herpesviruses have played an important role in Cancer Biology,
contributing signiﬁcantly to our comprehension of cell signaling and growth control pathways which lead to
malignancy. Unlike other infectious agents, herpesviruses persist in the host by establishing a latent infection,
so that they can reactivate periodically. Interestingly, some herpesviruses are able to either deliver or induce
the expression of cellular oncogenes. Such alterations can result in the derailment of the normal cell cycle and
ultimately shift the balance between continuous proliferation and programmed cell death. Herpesvirus
infection employs key molecules of cellular signaling cascades mostly to enhance viral replication. However,
most of these molecules are also involved in essential cellular functions, such as proliferation, cellular
differentiation and migration, as well as in DNA repair mechanisms. Ras proteins are key molecules that
regulate a wide range of cellular functions, including differentiation, proliferation and cell survival. A broad
ﬁeld of medical research is currently focused on elucidating the role of ras oncogenes in human tumor
initiation as well as tumor progression and metastasis. Upon activation, Ras proteins employ several
downstream effector molecules such as phosphatidylinositol 3-kinase (PI3-K) and Raf and Ral guanine
nucleotide-dissociation stimulators (RALGDS) to regulate a cascade of events ranging from cell proliferation
and survival to apoptosis and cellular death. In this review, we give an overview of the impact that herpesvirus
infection has on the host-cell Ras signaling pathway, providing an outline of their interactions with the key
cascade molecules with which they associate. Several of these interactions of viral proteins with member of
the Ras signaling pathway may be crucial in determining herpesviruses' oncogenic potential or their
oncomodulatory behavior. The questions that emerge concern the potential role of these molecules as
therapeutic targets both for viral infections and cancer. Understanding the means by which viruses may cause
oncogenesis would therefore provide a deeper knowledge of the overall oncogenic process.hrome c oxidase subunit II; E,
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1.1. Ras signaling pathway
Ras proteins are membrane-bound molecules that regulate a wide
range of cellular functions, including differentiation, proliferation and
cell survival [1]. A broad ﬁeld of medical research is currently focused
on elucidating the role of ras oncogenes in human tumor initiation as
well as tumor progression and metastasis [2]. More speciﬁcally, Ras
proteins are found to be mutated in many tumors such as melanoma,
ovarian and lung carcinoma [3,4]. Genetic alterations of ras genes
usually shift the balance between cell proliferation and cell death,
towards continuing proliferation and differentiation. The role of ras
genes during normal cellular function is dictated by the post-
translational modiﬁcation to which the proteins are subjected, which
is mainly farnesylation. This process determines the ﬁnal location of
the proteins in the cell, primarily the plasma membrane, as well as
their functionality. The enzyme farnesyl transferase links a farnesyl
group (15-carbon isoprenoid) covalently to a cysteine residue located
in the carboxy-terminal CAAX motif of Ras, allowing Ras to be
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Ras proteins are non-functional, probably due to the inability of these
proteins to employ their target enzymes and initiate signal transduc-
tion. Binding of ligands to tyrosine/kinase transmembrane receptors,
autophosphorylates their tyrosine residues in the cytosol. The tyrosine
residues serve as intracellular docking sites speciﬁc for several adaptor
molecules such as members of the SOS family. Ras proteins remain
inactive in the cell when they are bound to guanosine diphosphate
(GDP), but become activated when bound to guanosine triphosphate
(GTP) [5,6]. Ras is activated when ligand-bound receptors nucleate a
complex including adapter molecules [e.g., Src homology and collagen
(Shc; protein), Gab2, and growth factor receptor binding protein 2
(Grb2)], the phosphatase SHP-2, and guanine nucleotide exchange
factors (e.g., SOS). Guanine nucleotide exchange factors bind to Ras
and catalyze guanine nucleotide dissociation, which results in
increased Ras-GTP levels. Ras activation is terminated by hydrolysis
of GTP to GDP. This reaction is greatly accelerated by the GTPase-
activating proteins p120GAP and neuroﬁbromin.
Activation of Ras is responsible for the sequential phosphorylation of
downstream molecules which amplify and transduce signals from the
cell surface to the nucleus.More speciﬁcally, Ras proteins can employup
to 20 downstream effector molecules such as phosphatidylinositol 3-
kinase (PI3-K) and Raf and Ral guanine nucleotide-dissociation
stimulators (RALGDS) to regulate a cascade of events ranging from
cell proliferation and survival to apoptosis and cellular death [7–12]. The
activated Raf kinase, in particular, activates the MAPK cascade (Fig. 1).
The MAPK cascade in the mammalian cell comprises three well-Fig. 1. Host cell Ras signaling pathway. The key mediators of the pathway are represented
whether the virus up-, or down-regulates a speciﬁc cellular molecule.characterized protein kinases that are activated by protein phosphor-
ylation: aMAPK kinase kinase (MAPKKK), aMAPK kinase (MAPKK) and
ﬁnally a MAPK. The ﬁnal protein kinases (MAPKs) are the extracellular
regulated kinase (ERK1/2), p38 kinases, ERK5 and the c-Jun amino-
terminal kinases (JNK12/3). The Ras/Raf/MEK/ERK pathway is gener-
ally induced by cell surface receptors such as the Epidermal Growth
Factor Receptor (EGFR), whereas the p38 and JNK kinases respond to
stress signals as well as growth factor expression [13].
1.2. Herpesviruses and the Ras pathway
The Ras pathwaymolecules respond to various extracellular stimuli
which eventually determine the fate of the cell. Environmental,
chemical and infectious agents have the ability to affect the signaling
process in the cell, altering its physiological function. Human herpes-
viruses are of particular interest, since they are able to either induce
tumor initiation (oncogenic viruses), or regulate tumor behavior
(oncomodulatory viruses). Interestingly, 17.8% of worldwide cancer
cases are attributed to infectious agents, while 12.1% of the total cancer
cases are caused by viral infections [14]. Essentially, the above 12.1%
represents almost 70% of the total (17.8%) caused by infectious agents.
Bearing these epidemiological data in mind, as well as the
causative role of herpesviruses in several human diseases, involving
key signaling molecules of the host, we review this family of viruses
focusing on the Ras signaling pathway. Eight human herpesviruses
have been extensively studied and several of them have been
associated with the oncogenic Ras signaling pathway. In more detail,. Interactions between herpesviruses and host cell proteins are illustrated, indicating
779H. Filippakis et al. / Biochimica et Biophysica Acta 1803 (2010) 777–785the viruses are: Herpes Simplex Virus-1 (HSV-1 or HHV-1), Herpes
Simplex Virus-2 (HSV-2 or HHV-2), Human Herpes Virus Type 3
(HHV-3) or Varicella Zoster Virus (VZV), Epstein–Barr virus (EBV or
HHV-4), Human Cytomegalovirus (HCMV or HHV-5), Human Herpes
Viruses -6 and -7 (HHV-6 and HHV-7) and ﬁnally the Kaposi Sarcoma-
associated Herpes Virus (KSHV or HHV-8).
Upon infection of a host cell, a number of cellular defense
mechanisms are employed to eliminate the threat, followed by acute
inﬂammation. Although inﬂammation is generally considered to be
beneﬁcial for the cell, the environment of the inﬂammation site is a
very potent place for transformations to occur. During inﬂammation a
wide array of DNA-binding proteins, cytokines and chemokines are
recruited to combat the inﬂammatory signal. TNF-α, NF-κB, IL-1, COX-
2 and the pro-inﬂammatory chemokine families CXC and CC usually
have positive effects on cell proliferation. However, their ability to
cause DNA damage in the inﬂammation site has been shown to have a
negative effect on normal cell proliferation and angiogenesis [15–18].
Herpesviruses possess the ability to evade the host immune response
during initial exposure, and remain in a latent state until they
reactivate to carry out lytic infection [19,20]. Additionally, some
herpesviruses can promote oncogenesis either by delivering onco-
genes in the host cell or by activating cellular oncogenes. The
activation of oncogenes in the host cell leads to the expression of
transforming growth factors that deregulate normal cellular functions
and result in malignant cell transformation [21,22].
We provide an overview on the effect of herpesviral infection to
the host-cell Ras signaling pathway, focusing on gamma-herpes-
viruses and their association with the key cascade molecules with
which they interact.
2. Alpha-herpesviruses
Alpha-herpesviruses are the only subfamily of the herpesviridae
family, known as neurotropic pathogens. Thus, HSV and VZV are able
to infect and remain latent inside nerve cells and sensory ganglia.
Upon reactivation, the two viruses trigger a painful localized vesicular
rash. For HSV-1, it is usually lesions that form around the mouth area
of the infected individual, whereas for HSV-2 the outbreak is known as
genital herpes. VZV, on the other hand, is the causative agent of two
distinct clinical diseases: primary infection that leads to Varicella
(chickenpox) and reactivation from a latent state in sensory ganglia
that gives rise to zoster (shingles).
2.1. Herpes Simplex Virus type-1 and type-2 (HSV-1 and HSV-2)
Productive infection by HSV-1 involves the timely expression of
approximately 80 viral genes. These genes are expressed in three
sequential phases: Immediate Early (IE), Early (E) and Late (L). Many
products of these viral genes have been shown to interact with host
encoded proteins during infection in order to ablate the host-cell
defenses and ﬁnally replicate [23–27]. In addition, HSV-1 has the
ability to overcome cellular defense mechanisms in tumor as well as
in normal cells [28–32]. More speciﬁcally, experiments carried out on
H-ras transformed cell lines have shown that HSV-1 replicates in these
cells by inhibiting the virus-induced activation of the double-stranded
RNA-activated protein kinase (PKR) [33]. Phosphorylation of PKR
results in the phosphorylation of the translation initiation factor eIF-
2α, resulting in inhibition of the viral transcripts in the host cell. PKR
activation is essentially the major defense of the host cell against viral
infections.
PKR is also impaired by the expression of the HSV-1 neuroviru-
lence protein ICP34.5. ICP34.5 ablates host-cell PKR function by
inducing the dephosphorylation of eIF2α [34,35]. Inhibition of PKR
activity allows for the favorable expression of viral proteins, resulting
in impaired host-cell defense. Furthermore, HSV-1 establishes a latent
infection in sensory neurons in a Ras-dependent fashion [36].Infection in these cells by HSV-1 is characterized by the over-
expression of a series of transcripts, termed latency-associated
transcripts (LATs). Both Ras and Raf molecules are activated in
response to Neuronal Growth Factor (NGF) stimulation, which leads
to the activation of LATs and the establishment of latent infection [37].
In lytically infected cells, both HSV-1 and HSV-2 possess an anti-
apoptotic activity, as was previously described [38–40]. The two
viruses inhibit apoptosis in a cell type-speciﬁc manner. This inhibition
is attributed to the US3 gene, as well as to the US5 and ICP27 genes of
HSV-1 [41,42]. More speciﬁcally, expression of the HSV-1 ICP27
protein results in the enhanced activation of the p38 and JNK cellular
pathways [42]. Activation of the p38 pathway by ICP27 results in the
induction of apoptosis, whereas activation of the JNK pathway by
ICP27 requires the co-expression of one or more early or late viral
proteins. ICP27 appears to play a role as a pro-apoptotic factor for the
host cell since ICP27 expression alone cannot inhibit the apoptotic
signaling that takes place after p38 activation [43]. Induction of
apoptosis in cells infected by ICP27 mutant viruses, probably involves
the destabilization of Bcl-2, which is mediated by p38/MAPK pathway
activation. Bcl-2 loss of function is induced by p38 expression and
results in sensitization and induction of apoptotic cell death processes
[44]. Bcl-2 function in HSV-1 infected cells is crucial for the fate of the
host cell, and may prove to be a key mediator molecule for HSV-1
infection.
Interestingly, the HSV-2 tegument protein ICP10 PK [45–47],
appears to mediate activation of the host-cell Ras/Raf/MEK/ERK
pathway. Indeed, the levels of activated MAPK1/2 signiﬁcantly
increased in hippocampal cultures infected by HSV-2 when compared
to mock-infected cultures [48]. The inhibition of MAPKs by the
chemical inhibitor UO126 caused a dose-dependent increase in
apoptotic cells, suggesting that HSV-2 infection is actually mediated
through the cellular MAPK pathway, as shown in Fig. 1 [49]. Hence,
the infection of HSV-2 is mediated and enhanced by the host-cell ras
pathway since the viral ICP10 PK activates Ras, MEK and MAPK while
protecting the cell from apoptotic cell death [50,51].
Several studies have used mutant forms of HSV-1 and HSV-2 to
target tumor cells [52,53]. The mutant HSV forms are known as
oncolytic viruses since they are genetically modiﬁed to express their
proteins and replicate in tumor but not in normal cells [53,54]. These
conditionally replicating viruses infect and eventually kill tumor cells
either by inducing apoptosis, or by destroying these cells with the
cytolytic activity they possess [55,56]. For instance, the oncolytic
G207 HSV-1 strain is able to achieve enhanced permissiveness to
malignant peripheral nerve sheath tumors (MPNSTs). It is believed
that over-activation of Ras in MPNSTs leads to increased viral
replication in these cells and not in the normal ras expressing cells
[57].
Wild-type HSV-2 on the other hand is able to selectively replicate
and lyse tumor cells [58], such as neuroblastoma, renal, breast and
pancreatic cancers [59–61]. The abovementioned ICP10 PK protein of
HSV-2 is responsible for activating the Ras pathway leading to
deregulation of the cell cycle and uncontrolled proliferation.
Deletion of the PK subunit of the viral ICP10 protein impairs the
ability of HSV-2 to infect normal cells that have an inactive Ras
pathway [62]. Recent experimental data using recombinant Signal-
Smart (SS1) HSV-1 viruses, show that upon exposure of ELK-
overexpressing prostate cancer cells to the recombinant virus, the
cells' proliferation, invasiveness and colony formation capabilities
are signiﬁcantly decreased, whereas the rate of apoptosis/necrosis
functions is increased [63]. Additionally, increased Ras signaling cells
exposed to the recombinant virus, showed a conspicuous G1 cell
cycle arrest when compared to cells infected with parental HSV-1.
Oncolytic HSV-1 viruses provide an excellent tool to study oncogenic
signals and open novel paths in using these biological agents for
detection and targeting cancer cells, with augmented speciﬁcity and
efﬁciency.
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The Varicella Zoster Virus genome encodes approximately 70 gene
products, expressed in a timely fashion similar to the expression of
HSV proteins (IE, E and L). Lytic infection from the virus leads to
Varicella, a clinical manifestation also known as chickenpox that
includes symptoms such as fever and a generalized vesicular rash.
Reactivation of the virus from its latent state usually occurs during
adulthood and presents a distinct, localized vesicular rash that is
uncommon in herpesviral infections [64].
As with all herpesvirus infections, VZV-induced infections are
known to utilize host-cell signaling pathways in order to achieve
increased permissiveness [65]. Upon infection, the cell responds by
secreting, among others, interleukins (ILs). Interleukins and particu-
larly IL-8, play a crucial role in the immune response of the host cell,
since it acts as a keymediator during acute inﬂammationwith a variety
of actions on several tissues [66]. Secretion of IL-8 in VZV-infected T
cells is dependent of the status of both the JNK/SAPK and p38/MAPK
pathways. Hence, an active p38/MAPK pathway is required for IL-
8 secretion and a successful immune response in T cells [67].Moreover,
infection by VZV leads to the activation of theMAPKpathway by a two-
fold increase of p38/MAPK phosphorylation (Fig. 1), and ultimately to
the deregulation of the normal cell cycle and proliferation processes
[68–70]. Although there is a direct association of VZV infection with
the MAPK pathway, it remains unclear whether the virus interacts
with upstream molecules such as Ras, since current studies have
merely focused on the phosphorylation levels of MAPK, as well as the
characterization of two Open Reading Frames (ORF49 and ORF61)
[71,72]. ORF61 encodes proteins with transregulatory activities such
as the activation/phosphorylation of MAPKs in the host cell, whereas
ORF49 is synthesized at late infection stages since it is part of the virion
component.
3. Beta-herpesviruses
The beta-herpesviruses subfamily consists of the members HCMV,
HHV-6 and HHV-7. In order to gain entry into the host cell, beta-
herpesviruses, as with all herpesviruses, use virion envelope proteins
to adhere to the cell membrane and depose the virion components
into the cytoplasm. HCMV in particular, appears to infect a wide range
of cell types, such as ﬁbroblasts, endothelial cells, epithelial cells,
monocytes/macrophages, smooth muscle cells, neuronal cells, neu-
trophils, stromal cells and hepatocytes [73,74]. The broad cellular
tropism that HCMV demonstrates in the human body, justiﬁes the
increased manifestation of the virus in the worldwide population. On
the other hand, HHV-6 and HHV-7 are restricted to T lymphocytes and
certain cells of the myeloid lineage [69].
3.1. Human Cytomegalovirus (HCMV)
Human Cytomegalovirus is a widespread pathogen; an estimated
50–85% of the population worldwide is currently infected by HCMV
[75]. In particular, HCMV is able to remain latent in the monocyte-
macrophage cell lineage for extended periods of time, and is
reactivated when the individual is immuno-compromised [76]. Data
suggest that gene products of Human Cytomegalovirus can modulate
tumor cell biology, promoting mutagenesis, cell cycle progression,
angiogenesis, cell invasion and immune evasion [77,78].
There is increasing evidencewhich conﬁrms the presence of HCMV
in malignant tumors such as malignant glioblastoma [79,80], colon
cancer [81], as well as EBV-negative Hodgkin's lymphoma [82].
Studies on human colonic adenocarcinoma cells (Caco-2 cells), have
produced contradicting results. In one study the authors suggest that
Human Cytomegalovirus infection can only arise when Caco-2 cells
are in a speciﬁc state of differentiation, in which the virus does not
spread from cell to cell, and productive infection is rare, whereas theother group supports that Caco-2 cells are infected by HCMV,
regardless of the differentiation state [83,84]. In glioblastoma, the
HCMV Immediate Early-1 (72 kDa) protein (IE1) is expressed in N90%
of the tumors analyzed. A stable IE1 expression can differentially
affect the growth of human glioblastoma cells, resulting in either
growth proliferation or cell cycle arrest [85]. Given the high HCMV
infection rate in these tumors, it can be hypothesized that a sustained
expression of critical viral genes such as IE1 may have important
biological consequences in malignant glioma cells. Moreover, these
ﬁndings provide important insights into the pathogenic mechanisms
associated with aberrant signaling pathways, transcription factors
and/or tumor suppressor functions of the host cell.
Although HCMV is not directly associated with tumor formation,
the timely expression of its proteins regulates the host-signaling
pathways so that the virus can be sustained in the cell [86]. To
accomplish this, HCMV has to bind to speciﬁc cellular receptors in
order to initiate infection. Upon infection by HCMV, the viral particles
must ﬁrst enter the host cell and then travel to the nucleus in order to
initiate viral replication. Interestingly, HCMV entry into the host cell is
achieved by the synergistic action of the Epidermal Growth Factor
Receptor (EGFR) and the activation of the β3 integrin subunit. In turn,
this results in the activation of downstream molecules such as the
focal adhesion kinase, PI3K/Akt and phospholipase Cγ [87–89].
However, it is also argued that EGFR is not required for the cellular
expression of viral proteins or virus-induced signaling [90,91]. In
addition to EGFR and integrin, PDGFα and β have also been proposed
as cellular receptors for HCMV entry [92–94].
The binding of the viral particles to their respective receptors
[95,96] initiates a cascade of events that permit virus entry and
subsequent viral replication (Fig. 1). It is known that the Ras/Raf/
MEK/ERK pathway is activated when the phosphorylation of EGFR
occurs on the cell surface [97]. It is further believed that the gB
glycoprotein of HCMV shares common sequences with the Epidermal
Growth Factor (EGF), which acts as a ligand for EGFR [98,99], allowing
infection to occur.
Initial studies have shown that the steady-state levels of c-H-ras
increase in T2 cells upon RA-induced differentiation. Moreover, the
expression of exogenous oncogenic human H-ras in T2 cells allows for
HCMV infection, as well as changes in cell surface antigens observed in
the early stages of RA-induced differentiation [100]. Our recent
experimental data, obtained using H-ras transformed cells, further
support the enhanced permissiveness of HCMV augmenting the
progeny viral yield and the viral gene expression. Notably, HCMV
infection resulted in a further increase of the proliferation rate,
mobility and formation of cellular foci in the H-ras-activated cells
compared to mock-infected cells or the non-transformed parental cell
line (Filippakis, Spandidos, Sourvinos, unpublished data). These
observations suggest that HCMV employs the oncogenic Ras pathway
for the induction of cellular and/or viral gene expression and
enhanced viral permissiveness. The communication between viral
glycoproteins and cellular receptors is usually sufﬁcient to induce
activation of the ras pathway. However, there are several cellular
responses that follow infection, including the phosphorylation of
signaling kinases and the subsequent activation of transcription
factors, cytokines and prostaglandins. Successful HCMV infection
requires the activation of MEK1/2 and ERK1/2, two kinases that are
crucial elements of the Ras pathway [101]. Inhibition of these cellular
proteins by the inhibitors UO126 and PD098059 blocks the productive
HCMV infection in the cell, suggesting that the twomolecules are very
important for virus replication [102]. The abovementioned virus-
induced events impair the host-cell defense by interacting with
molecules of the Ras signaling cascade, thereby rendering the cell
more permissive to the virus. The relationship between HCMV and
cancer has been in the center of virology research for decades. The
frequent presence of a non oncogenic virus, such as HCMV, in
malignant tissues results in increased proliferation of HCMV-infected
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infect tumor cells and modulate their proliferation and overall
survival, without direct transformations taking place. These oncomo-
dulatory effects of HCMV infection arise from the interactions between
viral regulatory proteins and key signaling pathways such as the Ras/
Raf/MEK/ERK, p38 and Akt pathway [103].
3.2. Human Herpes Virus 6 and 7 or Roseolovirus (HHV-6, HHV-7)
HHV-6, which belongs to the beta subfamily of herpesviruses, was
isolated from peripheral blood mononuclear cells of patients with
lymphoproliferative disease [104]. Almost all children (95%) older
than 2 years of age are currently seropositive for HHV-6A/B. The
primary infection by HHV-6B sometimes causes exanthem subitum
(roseola infantum), which is a febrile rash illness [105]. HHV-7, which
also belongs to the same family of herpesviruses, was isolated in 1990
from the CD4+ lymphocytes of a healthy person [106]. HHV-6 exists in
variants A and B, and is a T-cell tropic virus that has been identiﬁed in
various human tumors [107]. Patients with Burkitt's, African and EBV-
negative B-cell lymphoma have been found to be seropositive for
HHV-6, and especially HHV-6B [108–110]. In addition, variant 6A of
the virus has been shown to contain a transformation suppressor
gene, called ts [111]. Cell lines that transiently expressed the ts gene
showed a signiﬁcant resistance to the transformation activity of Ras.
In the ts-expressing cells the transformation induced by Ras was
reduced by ∼98% when compared to the cells that do not express ts.
Furthermore, the ras gene promoter expressionwas reduced by ∼50%,
indicating that even a small decrease of ras expression plays a very
signiﬁcant role in its ability to transform. In vitro studies have
demonstrated that the viral ts gene can suppress the transcription
from the HIV-1 long terminal repeat (LTR) promoter, as well as ras
transformation at the promoter level. The transformation suppression
that takes place in ts-expressing HHV-6 infected cells is attributed to
the binding site of tswhich is common between the LTR promoter and
ras [112]. Unfortunately, there are insufﬁcient scientiﬁc data available
today to verify whether HHV-6 and -7 are able to implicate the Ras
signaling pathway to induce increased permissiveness or altered
cellular transformation. However, HHV-6 has been detected in
patients that develop ras-associated types of cancers such as bladder
cancer [113] or non-melanoma skin tumors [114], raising questions
about the role the virus might play in these patients.
4. Gamma-herpesviruses
The gamma-herpesviruses are the third subfamily of herpes-
viruses, including the Epstein–Barr virus and Kaposi's Sarcoma-
Associated Herpesvirus. EBV and KSHV are characterized as lympho-
tropic viruses, since they both have a cellular tropism for
lymphocytes. Unlike other human herpesviruses, the latent phase
of EBV and KSHV can be studied in vitro, providing an experimental
system that is unique among human herpesviruses. Latency of
gamma-herpesviruses is established after initial infection of the host
cell and transport of the capsid to the nucleus. The viral genome is
then able to replicate as an episome, utilizing the replication
mechanisms of the host cell. A unique characteristic of gamma-
herpesviruses is their ability to induce abnormal lymphocyte
proliferation and tumorigenesis. The balance between lytic and
latent infection is one of the most critical questions in modern
virology research. Although the exact mechanisms of gamma-
herpesviral reactivation need further study, it is believed that lytic
replication plays a crucial role in tumorigenesis [115]. Especially for
KSHV, low levels of periodical reactivation may lead to disease
development in the host and subsequent viral transmission to
uninfected cells. Viral reactivation in the host cell could also be
explained by the cell's microenvironment. For example, activation of
certain signaling pathways and the release of cytokines from thehost cell as a response to inﬂammation may provide a suitable
environment for the proliferation of infected cells [116].
4.1. Epstein–Barr virus (EBV)
EBV is able to infect a variety of cell types in the human body,
depending on the circumstances. Cells infected by EBV include NK-, T-,
smooth muscle and possibly follicular dendritic cells [117]. Several
human types of cancer such as Nasopharyngeal Carcinoma (NPC),
Burkitt's lymphoma (BL) and Hodgkin's disease (HD) have also been
attributed to EBV infection [118].
However, the virus preferentially infects and resides latently in
quiescent B memory cells [119]. Of note, however, is the mechanism
that the virus uses to evade host-cell immunity [120]. Once in the
latent phase, the virus is able to express several gene expression
motifs, depending on the location and differentiation state of the host
B cell [121]. In order to successfully remain in a latent state for an
extended period of time, EBV expresses a small subset of viral latent
genes that encode six Epstein–Barr nuclear antigens (EBNA1, 2, 3A,
3B, 3C, 4, 5 and 6), three membrane proteins (LMP1, LMP2A and
LMP2B), BART, as well as two small nuclear RNA molecules (EBER 1
and 2) [122]. The abovementioned genes are expressed in four
distinct patterns: type 0, 1, 2 and 3 [117,123,124]. During type 0
latency, EBVmay not express any genes ormay only express EBNA1 or
LMP2. In type 1, latency involves the expression of EBNA1 and EBER1
and 2 in Burkitt's lymphoma (BL) patients. In type 2 latency which is
found in Nasopharyngeal Carcinoma (NPC) and Hodgkin's lymphoma
(HL) patients, EBNA1, LMP1 and 2, EBERs and BARTs are expressed.
Finally, in the type 3 latency expression pattern, BARTs and EBERs are
expressed. Notably, of all the genes encoded by EBV during latency
only the LMP2A membrane protein induces the activation of the Ras
protein in vivo. The activated Ras protein induces the PI3K/Akt
cascade, but not the Raf/MEK/ERK pathway, to provide B-cell survival
and resistance to apoptosis (Fig. 1) [125,126].
EBV is also able to infect epithelial cells and affect cellular
transformation. To accomplish this, the virus expresses the integral
viral membrane protein LMP1. LMP1 has been found to be directly
associated with the activation of the MAPK cellular pathway in order
to activate the transcription factor AP-1 and regulate cell cycle [127].
Activation of a Ras-MAPK-dependent pathway by Epstein–Barr virus
latent membrane protein 1 causes prolonged ERK activation [128]
which is essential for cellular transformation [129]. Furthermore, this
pathway has been shown to contribute to the oncogenic nature of
LMP1 through its ability to promote cell motility and to enhance the
invasive properties of epithelial cells [130]. Therefore, LMP1 may act
as a constitutively active mechanism that ensures the survival of EBV-
infected B cells as well as their latency state, by interacting with the
Ras pathway. LMP2A provides signals of survival and maturation for B
cells, by inducing signaling patterns similar to the ones activated by
latent B cells. LMP1 in particular has been shown to bind and interact
with a vast number of transcription factors (AP-1), tumor necrosis
factor receptors (TRAFs), as well as intracellular signaling molecules
(p38, MAPKs, JNK), among others [131]. The increased binding afﬁnity
of LMP1 to host cell signaling cascades, such as the ras pathway,
originates from the increased homology that the viral protein shares
with the host-cell proteins.
4.2. Kaposi's sarcoma-associated Herpes Virus (KSHV)
KSHV is classiﬁed as an oncogenic virus which belongs to the
gamma-herpesvirus family. DNA sequences suggesting the presence
of a new virus were ﬁrst described in 1994 [132]. KSHV is associated
primarily with Kaposi's sarcoma [131,132], but is also known to cause
Primary Effusion Lymphoma (PEL) [133] and the multicentric variant
of Castleman Disease (MCD) [134]. During infection, the virus
employs the integrin α3/β1 subunit host-cell receptor in order to
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expresses a cascade of proteins that interact directly with cellular
signaling pathway components. In more detail, KSHV is known to
interact with the cytoplasmic, membrane-bound oncogenic protein
Ras [131,136]. The activation of Ras results in the activation of a series
of downstream components of both the PI3K and MAPK pathways as
indicated in Fig. 1. The two pathways are activated by Ras and are
responsible for cell growth, cell proliferation and programmed cell
death as previously described in this review. In particular, the K8 viral
protein, which is expressed during lytic infection, interacts with the
extracellular signal-regulated kinase (ERK). In the presence of an ERK
inhibitor (UO126) the expression of K8 was inhibited in a dose-
dependent manner [137]. Interestingly, the latent KSHV infection of
peripheral blood cells can shift towards lytic infection by chemical
inducers such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA) [138].
TPA induces lytic infection by activating the replication and
transcriptional activation (RTA) protein, which is encoded by ORF50
[139,140]. RTA controls the virus reactivation process by directly or
indirectly activating ORF59, vIL-6 and the K8 viral proteins. In
addition, the RTA protein expression is induced by transcription
factor AP-1, which is a downstream target of the three MAPK path-
ways mentioned above and is involved in cellular mechanisms of cell
growth, cell transformation and angiogenesis. Hence, the expression
of viral RTA protein is an indication of active viral replication and is
directly regulated by MEK/ERK, JNK and the p38 MAPK pathways
[141]. KSHV, as with all herpesviruses, is able to maintain a life-long
infection by remaining latent in the host. KSHV then reactivates
periodically by regulating cellular pathways such as MAPK and PI3K
[138]. Activation of the p38/MAPK as well as the JNK signaling
pathways is required for active KSHV infection to take place.
Inhibition of these pathways produced a dose-dependent regulation
of KSHV infection at the viral entry stage [142]. Additionally, the
overexpression of Raf, a ras effector molecule andmember of the Ras/
Raf/MEK/ERK pathway, leads to increased KSHV infectivity, an event
that takes place after attachment of the virus to the cell membrane
[143]. In addition, KSHV latency involves the expression of the latent
nuclear antigen 1 (LNA-1). Extensive research on the function of LNA-
1 revealed that it acts synergistically with the H-ras protein to induce
cellular proliferation and transformation [144].
5. Discussion
A signiﬁcant amount of effort has been invested by numerous
research groups in order to clarify the function of complex signaling
cascades. The Ras/Raf/MEK/ERK pathway was initially considered to
be a signal mediator, initiating outside the cell membrane and
concluding in the cell nucleus. However, signaling pathways are
implicated in a vast number of cellular functions, which in many cases
contradict each other. In modern day research, it is known that
information is transduced not only from the receptor to the nucleus,
but also between cascades. Since a large number of molecules
communicate with each other in the cytoplasm, the signal mediators
serve as a “pyramid” of information. The key components of each
pathway are located at the top of the “pyramid”. As the “pyramid”
opens, various signal mediators, such as the MAPK kinases start to
interact with molecules from different pathways to produce an
enormous array of responses and signals.
It is known that most of the existing infectious agents predate the
human race. Viruses in particular, have the capacity to evolve so
rapidly that modern science struggles to sustain the pace. The
frequent mutations that take place in herpesviral genomes produce
novel capsid recognition sites speciﬁc to host-cell surface receptors,
and ultimately aim to increase permissiveness to the host cell. Due to
their prevalence in the worldwide population, herpesviruses have
evolved to a point that they are able to manipulate host-cell
mechanisms to achieve enhanced permissiveness and ensure latentinfection. In their effort to replicate in vivo, herpesviruses alter the
mechanisms of cell division, proliferation and cell death, including the
Ras signaling pathway (Fig. 1).
The previous statement, however, does not fully apply to alpha-
herpesviruses since there is no concrete evidence associating HSV-1/-
2 infection to the altered proliferation of the host cell. Although
several HSV proteins appear to employ components of the Ras
signaling pathway, there are still a large number of viral proteins that
have not been studied. Research on VZV appears to be even more
obscure, probably due to the minimal scientiﬁc interest in the
transformation properties of the virus.
Beta-herpesviruses interact with the cellular cyclin proteins in
order to induce cell cycle arrest during infection. Once beta-
herpesviruses are able to replicate within the cell, they manipulate
the cell division process to increase the viral progeny. It is also widely
known that beta-herpesviruses are able to block apoptosis, a process
that would eventually result in their extinction. Although none of the
beta-herpesviruses has been implicated in malignancy, their impact
on the normal cell cycle and apoptosis raises signiﬁcant questions on
how they are able to modulate the cellular environment to their
advantage.
Gamma-herpesviruses, on the other hand, directly implicate host-
cell signaling processes in such a way that the physiological function
of the cell is derailed, resulting in the abnormal transformation of the
infected tissue. Furthermore, gamma-herpesviruses are able to both
mimic ligands speciﬁc for receptors such as EGFR and employ such
receptors in order to gain entry. The members of the MAPK family of
kinases (MEKK, MAPK and ERK) are also targeted by gamma-
herpesviruses. The Epstein–Barr virus, in particular, employs both
the MEKK kinase and PI3K to increase its virulence. The Human
Herpesvirus 8 is unique among herpesviruses due to its direct
association with the Kaposi sarcoma and due to the number of
cellular proteins it regulates. KSHV is able to interact with two
molecules of the Ras pathway, Raf and Erk, while it indirectly induces
the expression of PI3K and p38.
In summary, KSHV and EBV are the herpesviruses most involved
in the Ras signaling pathway. KSHV employs the ras pathway by
activating ras, PI3K, p38 and ERK1/2, whereas EBV activates MEK1/2
and PI3K kinases in order to promote cell proliferation and cell
survival respectively. Additionally, HSV-1 and HSV-2 induce the
expression of both ras and raf oncogenes, in order to promote
prolonged proliferation of the host cell and establish a latent
infection. Finally, HCMV, VZV and HHV6/7 are the less studied
herpesviruses as far as the Ras signaling pathway is concerned.
However, the discovery of the tumor-suppression activity of the
HHV-6 ts gene in ras-overexpressing tumors is of great importance
and its role should be investigated further, if we are to target HHV6
infection with gene therapy strategies. HCMV infection affects the
pathway upstream of ras, at the tyrosine kinase receptor level,
leaving many unanswered questions as to which speciﬁc molecules
of the Ras pathway are induced and/or inhibited. Furthermore, VZV
establishes a two-fold increase in p38/MAPK phosphorylation levels,
proving that the pathway is susceptible to manipulation. What
remains to be determined is whether the expression of VZV trans-
cripts is associated with activation of upstreammolecules such as Ras
and Raf.
Due to the highly intrusive nature of herpesviruses, the host cell is
rendered almost incapable of preventing the invasion. In addition,
herpesviral genomes stay well hidden as episomes inside the host,
opportunistically reactivating to cause severe inﬂammation and
damage to the host. Consequently, the host cells are fated to become
the “puppet” in the “hands” of the herpesvirus. Therefore, viral-
mediated oncogenesis research needs to combine the research ﬁelds
of Oncology and Virology. It is this unavoidable convergence of
expertise that will elucidate the role of herpesviruses in cancer and
ultimately produce a host-speciﬁc drug to combat cancer.
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